Personalized chemo dose could reduce side effects in lymphoma transplant patients
NCT ID NCT05540340
Summary
This study is testing a new, personalized way to calculate the dose of melphalan chemotherapy given to lymphoma patients before a stem cell transplant. Instead of using a standard dose based on height and weight, researchers are using a mathematical model to calculate an optimal dose for each person. They hope this personalized approach will be just as effective at treating the cancer but cause fewer side effects than the standard method.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.